Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | STK17B | O94768 | 1/20 | 0.30 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.30 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31601932 | 0.74 | FPR2 (0.34) | CCNT1L3MBTL1ZAP70SYKSTK17B | |
| SCHEMBL31601749 | 0.71 | NR1D1 (0.36) | L3MBTL1 | |
| SCHEMBL31601677 | 0.69 | GRM2 (0.34) | GRM2 | |
| SCHEMBL31601788 | 0.67 | PIK3CD (0.39) | — | |
| SCHEMBL18208911 | 0.67 | TTK (0.39) | TYK2 | |
| SCHEMBL1397620 | 0.66 | KDM4E (0.39) | CCNT1L3MBTL1STK17BSTK17AMAPT | |
| SCHEMBL31601780 | 0.65 | PIK3CD (0.39) | — | |
| SCHEMBL9134208 | 0.63 | L3MBTL1 (0.43) | L3MBTL1PTGESMAPT | |
| SCHEMBL19876859 | 0.63 | CCNT1 (0.44) | CCNT1L3MBTL1STK17BSTK17AMAPT | |
| SCHEMBL455120 | 0.63 | TTK (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025110815-A1 | IMIDAZO [1,2-B] PYRIDAZINE-BASED NOVEL COMPOUND AS CDK INHIBITOR AND USE THEREOF | 아이리드비엠에스 주식회사 | 2025-05-30 | — | — | WO | disclosed |